ALT shares drop over 20% after updated pemvidutide week 48 data; see FDA's stance on non-invasive fibrosis tests. Click here ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback